Journal of NeuroVirology

, Volume 23, Issue 1, pp 67–78 | Cite as

Evaluating the accuracy of self-report for the diagnosis of HIV-associated neurocognitive disorder (HAND): defining “symptomatic” versus “asymptomatic” HAND

  • Lisa C. Obermeit
  • Jessica Beltran
  • Kaitlin B. Casaletto
  • Donald R. Franklin
  • Scott Letendre
  • Ronald Ellis
  • Christine Fennema-Notestine
  • Florin Vaida
  • Ann C. Collier
  • Christina M. Marra
  • David Clifford
  • Benjamin Gelman
  • Ned Sacktor
  • Susan Morgello
  • David Simpson
  • J. Allen McCutchan
  • Igor Grant
  • Robert K. Heaton
  • The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) Group
Article
First Online:
Received:
Revised:
Accepted:

Abstract

The criteria for differentiating symptomatic from asymptomatic HIV-associated neurocognitive disorder require evaluation of (1) cognitive impairment, (2) daily functioning declines, and (3) whether the functional declines are attributable to cognitive versus physical problems. Many providers rely only on self-report to evaluate these latter criteria. However, the accuracy of patient-provided information may be limited. This study evaluated the validity of self-assessment for HIV-associated neurocognitive disorder (HAND) diagnoses by comparing objective findings with self-report of criteria 2 and 3 above. Self-reports were used to stratify 277 cognitively impaired HIV+ individuals into functionally dependent (n = 159) and independent (n = 118) groups, followed by group comparisons of objective functional problems. The dependent group was then divided into those who self-attributed their functional dependence to only cognitive (n = 80) versus only physical (n = 79) causes, for further comparisons on objective findings. The functionally dependent group was significantly worse than the independent group on all objective disability characteristics except severity of cognitive impairment, while those who attributed their dependence to physical (versus cognitive) factors were similar on all objective physical, cognitive, and functioning variables. Of note, 28 % of physical attributors showed no physical abnormalities on neuromedical examinations. Results suggest that patient report is consistently associated with objective measures of functional loss; in contrast, patient identification of physical versus cognitive causes is poorly associated with objective criteria. These findings caution against relying solely on patient self-report to determine whether functional disability in cognitively impaired HIV+ individuals can be attributed to strictly physical causes.

Keywords

AIDS Activities of daily living Self-assessment Cognitive disorders Etiology 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER; https://www.charterresource.ucsd.edu) is supported by awards N01 MH22005, HHSN271201000036C, and HHSN271201000030C from the National Institutes of Health. The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) group is affiliated with Johns Hopkins University; the Icahn School of Medicine at Mount Sinai; University of California, San Diego; University of Texas, Galveston; University of Washington, Seattle; and Washington University, St. Louis, and is headquartered at the University of California, San Diego, and includes Director Igor Grant, M.D.; Co-directors Scott L. Letendre, M.D., Ronald J. Ellis, M.D., Ph.D., and Thomas D. Marcotte, Ph.D.; Center Manager Donald Franklin, Jr.; Neuromedical Component: Ronald J. Ellis, M.D., Ph.D. (P.I.), and J. Allen McCutchan, M.D.; Laboratory and Virology Component: Scott Letendre, M.D. (Co-P.I.), and Davey M. Smith, M.D. (Co-P.I.).; Neurobehavioral Component: Robert K. Heaton, Ph.D. (P.I.), J. Hampton Atkinson, M.D., and Matthew Dawson; Imaging Component: Christine Fennema-Notestine, Ph.D. (P.I.), Michael J Taylor, Ph.D., and Rebecca Theilmann, Ph.D.; Data Management Component: Anthony C. Gamst, Ph.D. (P.I.), and Clint Cushman; Statistics Component: Ian Abramson, Ph.D. (P.I.), Florin Vaida, Ph.D., and Reena Deutsch, Ph.D.; Johns Hopkins University Site: Ned Sacktor (P.I.) and Vincent Rogalski; Icahn School of Medicine at Mount Sinai Site: Susan Morgello, M.D. (Co-P.I.), David Simpson, M.D. (Co-P.I.), and Letty Mintz, N.P.; University of California, San Diego Site: J. Allen McCutchan, M.D. (P.I.), and Kaori Phillips, B.S.N.; University of Washington, Seattle Site: Ann Collier, M.D. (Co-P.I.), Christina Marra, M.D. (Co-P.I.), and Sher Storey, PA-C.; University of Texas, Galveston Site: Benjamin Gelman, M.D., Ph.D. (P.I.), and Eleanor Head, R.N., B.S.N.; and Washington University, St. Louis Site: David Clifford, M.D. (P.I.), Muhammad Al-Lozi, M.D., and Mengesha Teshome, M.D. The views expressed in this article are those of the authors and do not reflect the official policy or position of the US Government.

Compliance with ethical standards

Study procedures were approved by the Human Subjects Protection Committees of each participating university. All participants provided written informed consent prior to study participation.

Conflict of interest

Ms. Obermeit is funded by a National Institute on Drug Abuse training grant DA031098. Ms. Casaletto is funded by a National Institute of Health grant F31DA035708. Mr. Franklin receives support from National Institute of Health grants HHSN271201000030C and HHSN271201000036C. Dr. Letendre receives support from National Institute of Health grants HHSN271201000036C, R01MH58076, R01MH92225, P50DA26306, and P30MH62512 and has received support for research projects from Abbott, Merck, Tibotec, and GlaxoSmithKline; has consulted for Gilead Sciences, GlaxoSmithKline, Merck, and Tibotec; and has received lecture honoraria from Abbott and Boehringer-Ingelheim. Dr. Ellis received National Institute of Health grants R01MH058076, U01MH83506, P30MH62512, R01MH83552, P50DA26306, R01MH095621, 2U01NS32228, and HHSN271201000036C and consultant fees from NeurogesX. Dr. Fennema-Notestine has received research support from National Institute of Health grants R01NS080655, R21DA037667, R01DA039775, R01AG048650, R03MH103995, and R01MH107345; R01 AG022381, P30 MH062512, and P50 DA026306; R01MH084796; and HHSN271201000036C. Dr. Vaida receives research support from National Institute of Health grants P30 MH62512, P50 DA26306, R01 MH083552, R01 AI47033, U01 AI74521, R01 MH085608, HHSN271201000030C, and HHSN271201000036C and Precision Photonics Corporation grant AI068543 and has served on a data safety and management board for Ardea Biosciences, Inc. Dr. Collier is supported by National Institute of Health grants MH22005, MH107345, AI069481, AI068636, AI120176, AI111806, NS082120, AI057005, DA037979, AI27757, and AI27767; had past research support from Bristol-Myers Squibb, Merck & Company, and Roche Molecular Systems; and is a member of a Data, Safety, and Monitoring Board for Merck-sponsored studies. Dr. Marra receives research support from National Institute of Health grants R01NS082120, R01NS34235, and R01MH107345 and receives royalties from Lippincott Williams and Wilkins and from UptoDate. Dr. Clifford is supported by National Institute of Health and Alzheimer Association grants NS077384, AI69495, NR012907, NR014449, NR012657, and UL1 TR000448; receives research support from Lilly and Roche; and has provided scientific advisory or consulting to Amgen, Biogen, Inhibikase, Genzyme/Sanofi, Takeda/Millennium, Roche/Genentech, Novartis, GSK, BMS, Pfizer, Quintiles, and Drinker Biddle & Reath (PML Consortium Scientific Advisory Board). Dr. Gelman receives support for National Institute of Health grants R01MH101017, R01MH107345, R01MH104134, R01NS072005, R01NS079166, R01DA036165, R56HL129881, and U24MH10093001. Dr. Sacktor receives support from National Institute of Health grants U01AI035042, RO1AG034852, HHSN271201000036C, RO1NS081196, RO1AG042165, P30MH075673, and RO1MH099733. Dr. Morgello receives support from National Institute of Health grants U24MH100931, R25MH080663, RO1MH107345, R21NR015009, R21DK105917, and RO1DA037611. Dr. Simpson receives research support from National Institute of Health grants U01MH083501, HHSN271201000027C, and UL1TR000067 and provided consultancy to GlaxoSmithKline and Gilead. Dr. McCutchan receives support from National Institute of Health grants P30MH62512, U01MH83506, U01AI69432, HHSN271201000036C, K30 RR22681, R01MH58076, and U13MH81676 and National Institute of Health/Centers for Disease Control and Prevention (CDC) grant U2G PS00623 and authors chapters on HIV for the Merck Manual. Dr. Grant receives support from National Institute of Health grants P30MH62512, P50DA26306, R01MH107345, 2RF1AG15301, R21DA036608, and R01MH094159. Dr. Heaton receives ongoing research support from National Institute of Health grants R01MH92225, P50DA26306, P30MH62512, R01MH60720, R01MH58076, R01MH78737, U01MH83506, R01MH83552, R01MH80150, and HHSN271201000036C.

References

  1. Ammassari A, Antinori A, Aloisi MS, Trotta MP, Murri R, Bartoli L, Monforte ADA, Wu AW, Starace F (2004) Depressive symptoms, neurocognitive impairment, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 45:394–402. doi: 10.1176/appi.psy.45.5.394 CrossRefPubMedGoogle Scholar
  2. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price W, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799. doi: 10.1212/01.WNL.0000287431.88658.8b CrossRefPubMedPubMedCentralGoogle Scholar
  3. Beck AT, Steer RA, Brown GK (1996) Beck depression inventory: second edition manual. San AntonioGoogle Scholar
  4. Blackstone K, Moore DJ, Heaton RK, Franklin DR, Woods SP, Clifford DB, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, Rivera-Mindt M, Deutsch R, Ellis RJ, Hampton Atkinson J, Grant I, CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Group (2012) Diagnosing symptomatic HIV-associated neurocognitive disorders: self-report versus performance-based assessment of everyday functioning. J Int Neuropsychol Soc 18:79–88. doi: 10.1017/s135561771100141x CrossRefPubMedGoogle Scholar
  5. Carey C, Woods S, Gonzalez R, Conover E, Marcotte T, Grant I, Heaton R (2005) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26:307–319. doi: 10.1080/13803390490510031 CrossRefGoogle Scholar
  6. Casaletto KB, Doyle KL, Weber E, Woods SP (2014) Self-predictions of prospective memory in HIV-associated neurocognitive disorders: evidence of a metamemory deficit. Arch Clin Neuropsychol 29:818–827. doi: 10.1093/arclin/acu061 CrossRefPubMedPubMedCentralGoogle Scholar
  7. Catz SL, Gore-Felton C, McClure JB (2002) Psychological distress among minority and low-income women living with HIV. Behav Med 28:53–60. doi: 10.1080/08964280209596398 CrossRefPubMedGoogle Scholar
  8. Chelune GJ, Heaton RK, Lehman RAW (1986) Neuropsychological and personality correlates of patients’ complaints of disability. In R. E. Tarter & G. Goldstein (Eds). Adv Clin Neuropsychol 3:95–126. doi: 10.1007/978-1-4613-2211-5_4 CrossRefGoogle Scholar
  9. Chiao S, Rosen HJ, Nicolas K, Wendelken LA, Alcantar O, Rankin KP, Miller B, Valcour V (2013) Deficits in self-awareness impact the diagnosis of asymptomatic neurocognitive impairment in HIV. AIDS Res Hum Retro 29:949–956. doi: 10.1089/aid.2012.0229 CrossRefGoogle Scholar
  10. Farrin L, Hull L, Unwin C, Wykes T, David A (2003) Effects of depressed mood on objective and subjective measures of attention. J Neuropsychiatry Clin Neurosci 15:98–104. doi: 10.1176/jnp.15.1.98 CrossRefPubMedGoogle Scholar
  11. Gould F, McGuire LS, Durand D, Sabbag S, Larrauri C, Patterson TL, Twamley EW, Harvey PD (2015) Self-assessment in schizophrenia: accuracy of evaluation of cognition and everyday functioning. Neuropsychology 29:675–682. doi: 10.1037/neu0000175 CrossRefPubMedPubMedCentralGoogle Scholar
  12. Grant I, Franklin DR, Deutsch R, Woods SP, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Collier AC, Marra CM, Clifford DB, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Smith DM, Heaton RK, CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Group (2014) Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology 82:2055–2062. doi: 10.1212/wnl.0000000000000492 CrossRefPubMedPubMedCentralGoogle Scholar
  13. Hart T, Giovannetti T, Montgomery MW, Schwartz MF (1998) Awareness of errors in naturalistic action after traumatic brain injury. J Head Trauma Rehabil 13:16–28. doi: 10.1097/00001199-199810000-00004 CrossRefPubMedGoogle Scholar
  14. Heaton RK, Taylor MJ, Manly JJ (2002) Demographic effects and use of demographically corrected norms with the WAIS-III and WMS-III. In: Tulsky D, Saklofske D, Chelune GJ, Heaton RK, Ivnik RJ, Bornstein R, Prifitera A, Ledbetter MF (eds.). Clinical interpretation of the WAIS-III and WMS-III. San Diego, CaliforniaGoogle Scholar
  15. Heaton RK, Marcotte TD, Mindt MR, Sadek J, Moore DJ, Bentley H, McCutchan JA, Reicks C, Grant I, HIV Neurobehavioral Research Center (HNRC) Group (2004a) The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 10:317–331. doi: 10.1017/s1355617704102130
  16. Heaton RK, Miller SW, Taylor MJ, Grant I (2004b) Revised comprehensive norms for an expanded Halstead-Reitan Battery: demographically adjusted neuropsychological norms for African American and Caucasian adults scoring program. OdessaGoogle Scholar
  17. Heaton RK, Clifford DB, Franklin DR, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CNS HIV Antiretroviral Therapy Effects Research (CHARTER) Group (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75:2087–2096. doi: 10.1212/wnl.0b013e318200d727 CrossRefPubMedPubMedCentralGoogle Scholar
  18. Hinkin CH, van Gorp WG, Satz P, Marcotte T, Durvasula RS, Wood S, Campbell L, Baluda MR (1996) Actual versus self-reported cognitive dysfunction in HIV-1 infection: memory-metamemory dissociations. J Clin Exp Neuropsychol 18:431–443. doi: 10.1080/01688639608408999 CrossRefPubMedGoogle Scholar
  19. Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, Thrasher D, Goetz MB, Stefaniak M (2002) Medication adherence among HIV+ adults effects of cognitive dysfunction and regimen complexity. Neurology 59:1944–1950. doi: 10.1212/01.wnl.0000038347.48137.67 CrossRefPubMedPubMedCentralGoogle Scholar
  20. Ickovics JR, Hamburger ME, Vlahov D, Schoenbaum EE, Schuman P, Boland RJ, Moore J, HIV Epidemiology Research Study Group (2001) Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. J Am Med Assoc 285:1466–1474. doi: 10.1001/jama.285.11.1466 CrossRefGoogle Scholar
  21. Johnson MK, Raye CL, Mitchell KJ, Touryan SR, Greene EJ, Nolen-Hoeksema S (2006) Dissociating medial frontal and posterior cingulate activity during self-reflection. Soc Cogn Affect Neurosci 1:56–64. doi: 10.1093/scan/nsl004 CrossRefPubMedPubMedCentralGoogle Scholar
  22. Juengst S, Skidmore E, Pramuka M, McCue M, Becker J (2012) Factors contributing to impaired self-awareness of cognitive functioning in an HIV positive and at-risk population. Disabil Rehabil 34:19–25. doi: 10.3109/09638288.2011.587088 CrossRefPubMedGoogle Scholar
  23. Kalechstein AD, Newton TF, van Gorp WG (2003) Neurocognitive functioning is associated with employment status: a quantitative review. J Clin Exp Neuropsychol 25:1186–1191. doi: 10.1076/jcen.25.8.1186.16723 CrossRefPubMedGoogle Scholar
  24. Karnofsky, DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. New YorkGoogle Scholar
  25. Kelly JA, Murphy DA, Bahr GR, Koob JJ, Morgan MG, Kalichman SC, Stevenson LY, Brasfield TL, Bernstein BM, St. Lawrence JS (1993) Factors associated with severity of depression and high-risk sexual behavior among persons diagnosed with human immunodeficiency virus (HIV) infection. Health Psychol 12:215–219. doi: 10.1037/0278-6133.12.3.215 CrossRefPubMedGoogle Scholar
  26. Knouse LE, Bagwell CL, Barkley RA, Murphy KR (2005) Accuracy of self-evaluation in adults with ADHD: evidence form a driving study. J Atten Disord 8:221–234. doi: 10.1177/1087054705280159 CrossRefPubMedGoogle Scholar
  27. Lawton MP, Brody EM (1969) Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontol 9(3):179–186Google Scholar
  28. Marcotte TD, Heaton RK, Wolfson T, Taylor MJ, Alhassoon O, Arfaa K, Grant I (1999) The impact of HIV-related neuropsychological dysfunction on driving behavior. J Int Neuropsychol Soc 5:579–592. doi: 10.1017/s1355617799577011 CrossRefPubMedGoogle Scholar
  29. Mausbach BT, Bowie CR, Harvey PD, Twamley EW, Goldman SR, Jeste DV, Patterson TL (2008) Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia. J Psychiatr Res 42:320–327. doi: 10.1016/j.jpsychires.2006.12.008 CrossRefPubMedGoogle Scholar
  30. McCutchan JA, Marquie-Beck JA, Fitzsimons CA, Letendre SL, Ellis RJ, Heaton RK, Wolfson T, Rosario D, Alexander TJ, Marra C, Ances BM (2012) Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology 78:485–492. doi: 10.1212/WNL.0b013e3182478d64 CrossRefPubMedPubMedCentralGoogle Scholar
  31. Morgan EE, Iudicello JE, Weber E, Duarte NA, Riggs PK, Delano-Wood L, Ellis R, Grant I, Woods SP, HIV Neurobehavioral Research Program (HNRP) Group (2012) Synergistic effects of HIV infection and older age on daily functioning. J Acquir Immune Defic Syndr 61:341–348. doi: 10.1097/QAI.0b013e31826bfc53 CrossRefPubMedPubMedCentralGoogle Scholar
  32. Norman MA, Moore DJ, Taylor M, Franklin D, Cysique L, Ake C, Lazarretto D, Vaida F, Heaton RK, The HNRC Group (2011) Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-revised, brief visuospatial memory test-revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-card version. J Clin Exp Neuropsychol 33:793–804. doi: 10.1080/13803395.2011.559157 CrossRefPubMedPubMedCentralGoogle Scholar
  33. O’Keeffe F, Dockree P, Moloney P, Carton S, Robertson I (2007) Characterising error-awareness of attentional lapses and inhibitory control failures in patients with traumatic brain injury. Exp Brain Res 180:59–67. doi: 10.1007/s00221-006-0832-9 CrossRefPubMedGoogle Scholar
  34. Pompili M, Pennica A, Serafini G, Battuello M, Innamorati M, Teti E, Girardi N, Amore M, Lamis DA, Aceti A, Girardi P (2013) Depression and affective temperaments are associated with poor health-related quality of life in patients with HIV infection. J Psychiatr Pract 19:109–117. doi: 10.1097/01.pra.0000428557.56211.cf CrossRefPubMedGoogle Scholar
  35. Scott JC, Woods SP, Vigil O, Heaton RK, Schweinsburg BC, Ellis RJ, Grant I, Marcotte TD, San Diego HIV Neurobehavioral Research Center (HNRC) Group (2011) A neuropsychological investigation of multitasking in HIV infection: implications for everyday functioning. Neuropsychology 25:511. doi: 10.1037/a0022491 CrossRefPubMedPubMedCentralGoogle Scholar
  36. Severeijns R, Vlaeyen JW, van den Hout MA, Weber WE (2001) Pain catastrophizing predicts pain intensity, disability, and psychological distress independent of the level of physical impairment. Clin J Pain 17:165–172. doi: 10.1097/00002508-200106000-00009 CrossRefPubMedGoogle Scholar
  37. Stuss DT (2011) Functions of the frontal lobes: relation to executive functions. J Int Neuropsychol Soc 17:759–765. doi: 10.1017/S1355617711000695 CrossRefPubMedGoogle Scholar
  38. Toglia J, Kirk U (2000) Understanding awareness deficits following brain injury. NeuroRehabilitation 15(1):57–70PubMedGoogle Scholar
  39. Tozzi V, Balestra P, Serraino D, Bellagamba R, Corpolongo A, Piselli P, Lorenzini P, Visco-Comandini U, Vlassi C, Quartuccio ME, Giulianelli M (2005) Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retrovir 21:706–713. doi: 10.1089/aid.2005.21.706 CrossRefPubMedGoogle Scholar
  40. van Gorp WG, Satz P, Hinkin C, Selnes O, Miller EN, McArthur J, Cohen B, Paz D (1991) Metacognition in HIV-1 seropositive asymptomatic individuals: self-ratings versus objective neuropsychological performance. J Clin Exp Neuropsychol 13:812–819. doi: 10.1080/01688639108401091 CrossRefPubMedGoogle Scholar
  41. Vigil O, Posada C, Woods SP, Hampton Atkinson J, Heaton RK, Perry W, Hassanein TI, Grant I, Letendre SL, HIV Neurobehavioral Research Center (HNRC) Group (2008) Impairments in fine-motor coordination and speed of information processing predict declines in everyday functioning in hepatitis C infection. J Clin Exp Neuropsychol 30:805–815. doi: 10.1080/13803390701802354 CrossRefPubMedPubMedCentralGoogle Scholar
  42. Woods SP, Rippeth JD, Frol AB, Levy JK, Ryan E, Soukup VM, Hinkin CH, Lazzaretto D, Cherner M, Marcotte TD, Gelman BB, Morgello S, Singer EJ, Grant I, Heaton RK (2004) Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol 26:759–778. doi: 10.1080/13803390490509565 CrossRefPubMedGoogle Scholar
  43. Woods SP, Morgan EE, Dawson M, Scott JC, Grant I, HIV Neurobehavioral Research Center (HNRC) Group (2006) Action (verb) fluency predicts dependence in instrumental activities of daily living in persons infected with HIV-1. J Clin Exp Neuropsychol 28:1030–1042. doi: 10.1080/13803390500350985 CrossRefGoogle Scholar
  44. World Health Organization (1998) Composite international diagnostic interview (CIDI, version 2.1). GenevaGoogle Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2016

Authors and Affiliations

  • Lisa C. Obermeit
    • 1
    • 2
  • Jessica Beltran
    • 1
  • Kaitlin B. Casaletto
    • 2
  • Donald R. Franklin
    • 1
  • Scott Letendre
    • 1
    • 3
  • Ronald Ellis
    • 1
    • 4
  • Christine Fennema-Notestine
    • 1
  • Florin Vaida
    • 5
  • Ann C. Collier
    • 6
  • Christina M. Marra
    • 7
  • David Clifford
    • 8
  • Benjamin Gelman
    • 9
  • Ned Sacktor
    • 10
  • Susan Morgello
    • 11
  • David Simpson
    • 12
  • J. Allen McCutchan
    • 3
  • Igor Grant
    • 1
  • Robert K. Heaton
    • 1
  • The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) Group
  1. 1.Department of PsychiatryUniversity of California, San DiegoSan DiegoUSA
  2. 2.SDSU/UCSD Joint Doctoral Program in Clinical PsychologySan DiegoUSA
  3. 3.Department of MedicineUniversity of California, San DiegoSan DiegoUSA
  4. 4.Department of NeurosciencesUniversity of California, San DiegoSan DiegoUSA
  5. 5.Department of Family Medicine & Public HealthUniversity of California, San DiegoSan DiegoUSA
  6. 6.Department of Medicine, Harborview Medical CenterUniversity of WashingtonSeattleUSA
  7. 7.Department of NeurologyUniversity of WashingtonSeattleUSA
  8. 8.Department of NeurologyWashington University in St. LouisSaint LouisUSA
  9. 9.Department of PathologyUniversity of Texas Medical BranchGalvestonUSA
  10. 10.Department of NeurologyJohns Hopkins UniversityBaltimoreUSA
  11. 11.Department of PathologyIcahn School of Medicine at Mount SinaiNew YorkUSA
  12. 12.Department of NeurologyIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations